|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Social Networking's 'Naked' Truth
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Geek Squad V. Gizmodo
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Blog You!!!
- Nora Tobin Answers Our Call
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
RSS FEED

![]() |
The $44 billion question, of course, is how much more. Shares of DNA keep hitting new highs as investors bet that Roche will revise. We've yet to hear a formal response from the three-member committee of independent directors that Genentech has formed to evaluate the bid.
In the meantime, I think we've got a new outlier on the speculated takeout price. Sanford C. Bernstein biotech analyst Geoffrey Porges is out with a research note to clients this morning titled, "Genentech: What would Genentech REALLY Be Worth? And Why $130/Share Is Not As Crazy As It Sounds."
Porges writes that his sum-of-the-parts analysis, which he details in the report, pegs DNA at $124 a share when he adds in drug development pipeline "opportunities" and drugs already on the market being approved in the future for other uses.
Porges gives an 80 percent chance of a deal getting done at $105/share or higher. And on his 20 percent odds that a deal falls through he sees a Genentech "stand-alone" valuation of $86 a share, which was his target price before Roche stepped in. Right now he has a $101 price target.
A part of Bernstein owns at least one percent of DNA shares.
This morning DNA is trading around $97.
P.S. A couple of weeks ago I reported that Food and Drug Administration Commissioner Dr. Andrew von Eschenbach had accepted a CNBC invitation to guest host "Squawk Box" this Thursday.
Well, I'm disappointed, to say the least, that this morning a spokesman--not the spokesperson who had formally confirmed his appearance via email several weeks ago--told a Squawk producer/booker that the commish has to cancel because of a "scheduling conflict."
Questions? Comments?







